HHC
hexahydrocannabinol
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
HHC (hexahydrocannabinol) is a semi-synthetic cannabinoid of the classical cannabinoid class. It is the fully saturated structural analog of Δ⁹-THC, with the active epimer matching THC's potency at CB1.[1] HHC is a partial CB1 receptor agonist, producing its effects by disrupting retrograde neurotransmitter signaling across mood, memory, and motor circuits.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized by Roger Adams in 1940 as part of foundational cannabinoid structure-activity research, HHC served as a pharmacological tool compound for over eight decades.[2] It appeared on recreational markets around 2021, exploiting the hemp-derived CBD supply chain created by the 2018 US Farm Bill.[3] By 2024, 36 countries had reported HHC to UNODC, and the WHO recommended Schedule II placement under the 1971 Convention on Psychotropic Substances.[4]
Subjective effects include euphoria, sedation, altered time perception, appetite enhancement, and cognitive impairment. The experience closely resembles Δ⁹-THC intoxication — a warm, slowing sedation with mild perceptual shifts — though variable epimer ratios in commercial products make intensity unpredictable between batches.[5][6] Anxiety, paranoia, and psychomotor impairment are characteristic unsought effects.
No physical dependence data exist for HHC specifically, though abuse liability comparable to Δ⁹-THC is expected from shared CB1 agonism; acute oral toxicity in rats is low.[7] The primary risk is product-level unpredictability — batch-to-batch variation in epimer composition and possible contamination from semi-synthetic manufacture mean nominally identical doses can produce markedly different effects.[6] No clinical trials have been conducted, and the current understanding rests on two small pilot studies, one animal toxicity investigation, and class inference from Δ⁹-THC pharmacology.
History[edit]
Discovery
HHC was first synthesized by Roger Adams at the University of Illinois in 1940, during a systematic investigation of tetrahydrocannabinol analogs aimed at identifying the psychoactive principles of cannabis.[2] The synthesis involved catalytic hydrogenation of Δ⁹-THC, fully saturating the cyclohexene ring to produce the hexahydro derivative. A US patent describing the process was filed in 1944 and granted in 1947.[8]
Research tool
For the next eight decades, HHC functioned primarily as a pharmacological tool compound for studying cannabinoid structure-activity relationships. The distinction between its two epimers — the active (9R) form and the weakly active (9S) form — was recognized early and rigorously confirmed through molecular modeling in 1989.[9] From the 1990s onward, HHC served as a scaffold for medicinal chemistry programs exploring controlled-deactivation cannabinergic ligands.citation needed
Market emergence and scheduling
HHC appeared on the US recreational market in approximately September 2021, manufactured from hemp-derived CBD through a two-step semi-synthesis exploiting the 2018 Farm Bill's legalization of hemp.[3] It reached European markets by May 2022 and became the predominant semi-synthetic cannabinoid in multiple jurisdictions by 2023. The WHO Expert Committee on Drug Dependence recommended Schedule II placement under the 1971 Convention in October 2024,[4] ratified in March 2025, and the US DEA assigned HHC a specific Schedule I drug code in May 2026.[10]
The name "hexahydrocannabinol" reflects its chemical relationship to THC — "hexahydro" indicating the six hydrogen atoms added to fully saturate the C-ring. Commercial shorthand distinguishes the epimers as "alpha-HHC" (the weak (9S) form) and "beta-HHC" (the active (9R) form), though these labels are inconsistently applied across vendors.
Chemistry[edit]
Structural class
HHC belongs to the classical cannabinoid family, sharing the dibenzopyran scaffold common to Δ⁹-THC and related compounds. It is the fully saturated structural analog of THC — the double bond in THC's cyclohexene ring is reduced to a single bond, converting the partially unsaturated ring into a fully saturated cyclohexane. The pentyl side chain, phenolic hydroxyl, and geminal dimethyl group critical for cannabinoid receptor binding are all retained.[3]
Commercial HHC is synthesized from hemp-derived CBD in two steps: acid-catalyzed cyclization of CBD to a Δ⁸/Δ⁹-THC mixture, followed by catalytic hydrogenation.[3]
| Molecular formula | C₂₁H₃₂O₂ |
| Molecular weight | 316.5 g/mol |
Stereochemistry
HHC has three chirality centers: C6a, C9, and C10a. Hydrogenation of THC's double bond creates the critical C9 center, yielding two diastereomers with dramatically different activity.
(9R)-HHC (beta-HHC) is the pharmacologically active epimer. Molecular modeling shows the (9R) configuration locks the C-ring into a chair conformation that positions the methyl group equatorially — the geometry required for optimal CB1 engagement.[9]
(9S)-HHC (alpha-HHC) is weakly active. Its C-ring adopts less favorable conformations for receptor binding.[9]
These diastereomers do not interconvert under physiological conditions. Laboratory hydrogenation using Adams' catalyst (PtO₂) favors the active (9R) form at roughly 7:1,[11] but commercial products show extreme variability — analysis of over 60 products found (9R):(9S) ratios ranging from 0.2:1 to 2.4:1.[6]
Natural occurrence
HHC occurs in trace quantities in cannabis pollen and seeds.[12] These concentrations are pharmacologically irrelevant. The question of natural occurrence is legally contested: the DEA has stated HHC can "only be obtained synthetically",[10] while published phytochemistry documents its presence in plant material.[12]
Pharmacology[edit]
Mechanism of action
HHC is a partial agonist at the cannabinoid CB1. Both the (9R) and (9S) epimers bind CB1, but the active (9R) form is roughly 12 times more potent than the (9S) form in functional assays.[1] The (9R) epimer's potency is comparable to that of Δ⁹-THC.
The stereospecific difference arises from ring geometry: the (9R) configuration constrains the C-ring into a shape that positions the methyl group optimally for the CB1 binding pocket, while the (9S) form adopts less favorable orientations.[9][1]
In β-arrestin2 recruitment assays, HHC showed higher CB1 activation potential than Δ⁹-THC.[13] The WHO ECDD concluded that HHC has preferential affinity for CB1 over CB2, consistent with its sedative, analgesic, and anxiogenic properties.[4]
No binding affinity values from displacement assays have been published for unmodified HHC.[6] No data on CB2 potency or downstream signaling bias specific to HHC exist.
Pharmacokinetics
Two controlled pilot studies (n = 3 per group each) provide the primary pharmacokinetic data for HHC. Both administered 25 mg doses orally and via inhalation.
After inhalation, peak plasma concentrations of the (9R) epimer reached approximately 65 ng/mL within about 5 minutes. After oral administration, peak levels were substantially lower — approximately 3.8 ng/mL — and appeared at roughly 1 hour.[14] The overall pharmacokinetic profile was comparable to Δ⁹-THC, with route of administration and individual variability as the dominant determinants.[15]
Oral metabolites identified include a hydroxylated form and the corresponding carboxylic acid. In a forensic case series of 599 serum samples from suspected cannabis users, 25 tested positive for HHC, with (9R)-HHC concentrations of 0.15–14.4 ng/mL.[16]
No human bioavailability, volume of distribution, protein binding, or half-life data have been published.
Neuroscience[edit]
Where it acts
HHC activates CB1 receptors concentrated in the hippocampus, basal ganglia, cerebellum, amygdala, and prefrontal cortex. As an exogenous partial agonist, it overrides the brain's tightly regulated endocannabinoid retrograde signaling — activating CB1 receptors independently of physiological demand rather than in response to specific neural activity patterns.inferred
This global disruption accounts for the breadth of acute effects: hippocampal CB1 activation impairs memory encoding, amygdala modulation produces dose-dependent shifts between relaxation and anxiety,[7] cerebellar and basal ganglia effects drive motor impairment,[15][14] and prefrontal disruption underlies cognitive impairment and decision impairment.
Why it matters
The endocannabinoid system operates as a demand-driven network — signaling molecules are synthesized and released only when specific neural activity calls for them. Exogenous agonists like HHC bypass this precision, producing simultaneous activation across circuits that normally operate independently. This explains why cannabinoid intoxication spans cognitive, emotional, and motor domains at once.
CB1 agonism in the mesolimbic mesolimbic pathway disinhibits dopamine neurons, driving the reinforcing and euphoric properties of cannabinoids while enhancing motivational salience of stimuli — particularly food, accounting for appetite enhancement.
No neuroimaging or electrophysiological studies specific to HHC have been conducted. Whether HHC produces the same pattern of CB1 receptor downregulation as Δ⁹-THC with chronic use — and whether it recovers on the same 2–4 week timeline — is unknown.
Subjective Effects[edit]
The HHC experience is that of a conventional cannabinoid intoxication: a settling warmth, softened edges on sensory input, and a slowing of internal tempo. At lower doses the character is gently sedating and mildly euphoric; at higher doses the sedation deepens, cognitive coherence fragments, and anxiety or paranoia may intrude. Set and setting modulate the experience meaningfully — social contexts tend toward humor and relaxation, while isolated or anxious settings amplify the compound's paranoid and ruminative potential.
Users consistently compare HHC to Δ⁹-THC, describing it as qualitatively similar but somewhat reduced in overall intensity.[5][6] This perceived potency gap likely reflects the diluting presence of the weakly active (9S) epimer in most commercial preparations rather than a fundamental pharmacological difference at the receptor level.
Effect Grid
Clear cannabinoid intoxication — unmistakable euphoria, noticeable sedation, and distinct time alteration. Thought deceleration becomes prominent, with ideas arriving more slowly but sometimes feeling richer or more connected. Music enhancement and humor enhancement are reliably present. Appetite enhancement is typically strong.
Physically, dry mouth is common, body high is well-established, and motor control impairment becomes noticeable — walking and fine manipulation are measurably affected. Cognitive impairment includes memory suppression and focus suppression. Anxiety is possible in sensitive individuals, particularly in unfamiliar settings.
This is the dose range where controlled studies documented measurable psychomotor impairment. Do not drive or operate machinery.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Taste enhancement · Touch enhancement · Brightness alteration · Color alteration · Depth perception distortion · Perspective distortion · Sound sensitivity · Visual haze / noise · Olfactory enhancement · Sleep-transition hallucinations · Auditory distortion · Auditory misinterpretation · Light sensitivity · Proprioceptive distortion · Vestibular distortion · Visual acuity suppression · After-images · Flashbacks · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations
Color alteration · Depth perception distortion · Perspective distortion · Sound sensitivity · Visual haze / noise · Olfactory enhancement · Sleep-transition hallucinations · Auditory distortion · Auditory misinterpretation · Light sensitivity · Proprioceptive distortion · Vestibular distortion · Visual acuity suppression · After-images · Flashbacks · Visual processing suppression · Internal hallucinations · Auditory hallucinations · External hallucinations
Body scan awareness · Heart rate perception changes · Muscle relaxation · Sedation · Bodily heaviness · Dizziness · Laughter fits · Nausea suppression · Pain suppression · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Watery eyes · Constipation · Dehydration sensation · Bodily lightness · Bodily pressures · Body schema distortion · Breathing alteration · Nausea · Nystagmus (eye wobbles) · Restlessness · Sexual arousal enhancement · Temperature dysregulation · Vomiting · Bodily dissociation
Sedation · Bodily heaviness · Dizziness · Laughter fits · Nausea suppression · Pain suppression · Physical fatigue · Spontaneous body sensations · Tactile euphoria · Watery eyes · Constipation · Dehydration sensation · Bodily lightness · Bodily pressures · Body schema distortion · Breathing alteration · Nausea · Nystagmus (eye wobbles) · Restlessness · Sexual arousal enhancement · Vomiting · Bodily dissociation
Cognitive impairment · Focus suppression · Analysis suppression · Cognitive fatigue · Humor enhancement · Immersion enhancement · Information processing suppression · Introspection enhancement · Memory fragmentation · Novelty enhancement · Thought connectivity · Thought disorganization · Creativity enhancement · Conceptual thinking · Confusion · Delusions of sobriety · Language suppression · Motivation suppression · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought deceleration · Thought loops · Cognitive dysphoria · Thought acceleration · Amnesia · Delusions
Cognitive fatigue · Humor enhancement · Immersion enhancement · Information processing suppression · Introspection enhancement · Memory fragmentation · Novelty enhancement · Thought connectivity · Thought disorganization · Creativity enhancement · Conceptual thinking · Confusion · Language suppression · Motivation suppression · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Suggestibility enhancement · Thought deceleration · Thought loops · Cognitive dysphoria · Thought acceleration · Amnesia · Delusions
Emotional lability · Dysphoria · Irritability
Disinhibition · Emotional susceptibility · Automaticity · Depersonalization · Social connection · Social disconnection · Cognitive disconnection
Social connection · Social disconnection · Cognitive disconnection
Timeline
Gradual awareness of body heaviness and a subtle mood shift. Effects may be difficult to distinguish from expectation for 30-60 minutes.
Building euphoria, emerging sedation, and the first clear perceptual changes — time begins to stretch, appetite stirs. Body high establishes.
Full cannabinoid intoxication — euphoria, sedation, time alteration, appetite enhancement, cognitive impairment, and motor control impairment are all at maximum intensity.
Gradual reduction in intensity. Sedation and body heaviness tend to persist longest while euphoria and perceptual effects recede first.
Residual sedation, mild cognitive fog, and possible lingering appetite effects. Some users report a pleasant, mellow quality.
⚠ Do not drive or operate machinery for at least 8 hours after oral HHC use — residual impairment may persist beyond subjective return to baseline.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- Δ⁹-THC · Δ⁸-THC · Other CB1 agonists
Toxicity
Acute toxicity
Acute oral toxicity is low. The only published data come from a single animal study: a 1:1 epimer mixture administered to male rats yielded an estimated LD₅₀ of approximately 1000 mg/kg (OECD Category 4), placing HHC in the same low-acute-toxicity range as Δ⁹-THC.[7] No human overdose case series exists for standard pentyl-chain HHC.safety citation needed
Adverse events from HHC homologs
Published case reports of severe adverse events involve longer-chain HHC homologs, not standard pentyl-chain HHC. Two patients were hospitalized after HHC-C8 (octyl homolog) intoxication — one experienced coma lasting 2 days with recurring seizures, the other prolonged sedation for 3 days.[17] A separate case involving HHC-C9 (nonanyl homolog) resulted in 9 days of cognitive and physical impairment.[18]
These cases reflect the increased potency of longer-chain homologs and illustrate the risk of product mislabeling or contamination within the HHC chemical family.
Product contamination
Commercial products carry contamination risks from semi-synthetic manufacture: variable epimer ratios producing batch-to-batch potency inconsistency,[6] possible residual Δ⁸/Δ⁹-THC and catalyst residues,[19] and uncharacterized thermal decomposition products from vaping HHC-O (acetate ester) if co-present.safety citation needed
Psychological risks
Anxiety and paranoia are dose-dependent effects — lower doses tend toward anxiolysis, higher doses toward anxiogenesis, consistent with established CB1 agonist pharmacology.[7]
Psychosis risk is biologically plausible. The 2024 European Web Survey on Drugs documented reports of psychotic illness precipitated by HHC use in Ireland,[20] though no formal case series has been published. Threshold dose, frequency, and individual vulnerability factors for HHC-precipitated psychosis are uncharacterized.
Acute cognitive impairment — including impaired sensorimotor gating,[7] psychomotor impairment,[15][14] and memory disruption — occurs during active intoxication. Duration and reversibility of cognitive effects after repeated use have not been studied.
Tolerance & dependence
No HHC-specific tolerance or dependence data have been published. No reports of HHC withdrawal exist in the peer-reviewed literature.
By class inference from CB1 agonist pharmacology: tolerance develops through downregulation within days to weeks of daily use. Cross-tolerance with Δ⁹-THC is expected given the shared CB1 mechanism.inferred
Dependence liability comparable to Δ⁹-THC (approximately 9% of regular cannabis users develop dependence) is expected, though HHC's partial agonist nature may somewhat attenuate this risk.inferred The Ireland Web Survey documented HHC use patterns but did not publish quantitative dependence data.[20]
Drug interactions
No HHC-specific drug interaction studies exist. All interactions below are inferred from cannabinoid class pharmacology.inferred
Metabolic interactions
Cannabinoids including Δ⁹-THC and CBD inhibit liver enzymes (CYP2C9, CYP2C19, CYP3A4) involved in metabolizing many common medications.[21][22] HHC is expected to share these interactions. Clinically significant risks include:
- Warfarin: increased bleeding risk
- Clopidogrel: reduced antiplatelet effect
- Anti-seizure medications (phenytoin, carbamazepine, valproate): altered drug levels
- Benzodiazepines (midazolam, alprazolam): increased sedation and prolonged effects
Pharmacodynamic interactions
- CNS depressants (alcohol, opioids, benzodiazepines, sedating antihistamines): additive sedation, motor impairment, and respiratory depression
- Other cannabinoids: additive effects at CB1; particularly relevant given residual Δ⁸/Δ⁹-THC in some products[19]
- Anticholinergics: additive dry mouth, fast heart rate, and cognitive impairment
Contraindications
No HHC-specific contraindication studies exist. The following are inferred from CB1 agonist pharmacology.inferred
Absolute:
- Personal or family history of psychotic disorders: CB1 agonism is an established risk factor for precipitating and worsening psychotic illness[20]
- Pregnancy and lactation: exogenous CB1 agonists disrupt endocannabinoid-dependent brain developmentsafety citation needed
Relative:
- Heart conditions: CB1 agonists cause increased heart rate and blood vessel dilationsafety citation needed
- Anxiety disorders: dose-dependent anxiety documented in animal models[7]
- Cannabis use disorder (active or in remission): shared mechanism and expected cross-reinforcement
- Liver impairment: may prolong drug exposure and increase adverse effects
- Concurrent medications metabolized by CYP2C9/3A4: see Drug Interactions
- Adolescence: neurodevelopmental vulnerability to CB1 agonism is well established for Δ⁹-THC
Harm Reduction[edit]
Forms & Identification
HHC products present a unique identification challenge: the active (9R) and weakly active (9S) epimers are chemically indistinguishable without laboratory analysis, yet they differ roughly 12-fold in potency. Standard reagent tests cannot differentiate HHC from Δ⁹-THC or Δ⁸-THC, and no field test distinguishes between the epimers.
The practical implication is that labeled potency on commercial HHC products is unreliable. Two products claiming identical HHC content may deliver very different experiences depending on their epimer ratio. Third-party certificates of analysis that report total HHC without specifying the (9R):(9S) split provide incomplete safety information.
Guidelines
- Test a low dose from any new product or batch before committing to a full dose — epimer ratios vary unpredictably between manufacturers
- Avoid driving or operating machinery; psychomotor impairment is documented even at moderate doses[15][14]
- Oral administration has a delayed onset (1–2 hours); wait the full onset window before redosing
- Have food and water accessible — appetite enhancement and dry mouth are common
- If prone to anxiety or panic, start very low and use only in a comfortable setting with a trusted person present
Set & Setting
HHC's dose-dependent shift from relaxation to anxiety makes environmental context particularly important. A calm, familiar environment with trusted companions reduces the likelihood of paranoid or anxious responses. Novel or high-stimulation settings — crowds, unfamiliar locations, social pressure — amplify the anxiogenic potential at moderate-to-high doses.
First-time users and those switching products or batches should treat each new source as an unknown quantity. Epimer variability between products means prior experience with one brand does not reliably predict the intensity of another.
Aftercare & integration. HHC's cognitive effects — particularly memory disruption and mental fog — may linger for several hours after the primary experience subsides. Plan for a recovery window: avoid demanding cognitive tasks, drive only after full clarity returns, and allow extra sleep if needed.
Hydration and light food help counter the dry mouth and appetite disruption common during the tail end of effects. If anxiety or paranoia were prominent during the experience, grounding techniques (focused breathing, physical contact with a familiar object, verbal reassurance from a companion) can help re-establish baseline.
Recovery & Support
Regular HHC use carries expected dependence risk comparable to cannabis. Signs of problematic use include escalating doses, using to manage anxiety or sleep despite worsening baseline function, and difficulty stopping despite wanting to.
Cannabis-specific support resources apply to HHC use: Marijuana Anonymous (ma-online.org), SMART Recovery, and local substance use counseling services. A healthcare provider familiar with cannabinoid dependence can help develop a tapering strategy if abrupt cessation proves difficult.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Most uncomfortable HHC experiences resolve on their own with time and reassurance. Seek immediate help if any of the following occur: chest pain or irregular heartbeat, seizures, loss of consciousness, severe confusion or psychotic symptoms (loss of contact with reality, extreme paranoia, self-harm risk), or prolonged vomiting.
- Call emergency services immediately if the person is unresponsive, seizing, or expressing intent to harm themselves
- Place an unconscious but breathing person in the recovery position (on their side)
- Do not leave the person alone
- Do not induce vomiting
- Keep the environment calm, reduce stimulation, and speak in a steady voice
Tell the dispatcher: what was taken (HHC), approximate amount and time of ingestion, the route of administration (vaped, eaten), and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
HHC is controlled in a growing number of jurisdictions following the WHO ECDD recommendation for Schedule II placement under the 1971 Convention on Psychotropic Substances,[4] ratified by the UN Commission on Narcotic Drugs in March 2025. The compound's rapid market emergence beginning in 2021, followed by a wave of national prohibitions from 2023 onward, exemplifies the regulatory challenge posed by semi-synthetic cannabinoids derived from legal hemp precursors. In the United States, a DEA final rule published May 4, 2026, assigned HHC the specific Schedule I drug code 7220.[10]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Drug code 7220 assigned May 4, 2026[10] |
| United Kingdom | Controlled under Psychoactive Substances Act 2016 | Production, supply, and import for human consumption are illegal |
| France | Banned | Among first EU member states to prohibit HHC (2023) |
| Germany | Controlled (Narcotics Act) | Added to controlled substances list in 2023 |
| Austria | Controlled | Added to controlled substances in 2023 |
| Poland | Controlled | Effective April 14, 2023 |
| Sweden | Classified as narcotic | HHC and HHCP scheduled simultaneously, effective July 11, 2023[23] |
| Ireland | Controlled | HHC sold openly until July 2025; subsequently controlled[20] |
| International (UN) | Schedule II, 1971 Convention on Psychotropic Substances | WHO ECDD recommendation (October 2024) ratified March 2025[4] |
| Canada | Not confirmed | No specific scheduling information verifiedcitation needed |
| Australia | Not confirmed | No specific scheduling information verifiedcitation needed |
references
- [1] ^abcHaghdoost M, López de Los Santos Y, Brunstetter M, Ferretti ML, Roberts M, Bonn-Miller MO (2024) Using In Silico Molecular Docking to Explain Differences in Receptor Binding Behavior of HHC and THCV Isomers: Revealing New Binding Modes — Pharmaceuticals doi:10.3390/ph17050637
- [2]
- [3] ^abcdUjváry I (2024) Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review — Drug Testing and Analysis doi:10.1002/dta.3519
- [4]
- [5] ^abCaprari C, Ferri E, Vandelli MA, Citti C, Cannazza G (2024) An emerging trend in Novel Psychoactive Substances (NPSs): designer THC — Journal of Cannabis Research doi:10.1186/s42238-024-00226-y
- [6]